Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy

References

• Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172:782–794.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–592.
   PubMed Web of Science ®Google Scholar
• Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012;40:21–41.
   PubMedGoogle Scholar
• Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers. 2014;2:e29528.
   PubMedGoogle Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115:10938–10966.
   PubMed Web of Science ®Google Scholar
• Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352–3356.
   PubMed Web of Science ®Google Scholar
• Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164:138–144.
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412–2417.
   PubMed Web of Science ®Google Scholar
• Hansen AE, Petersen AL, Henriksen JR, et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano. 2015;9:6985–6995.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013;4:81–89.
   PubMed Web of Science ®Google Scholar
• Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv Drug Deliv Rev. 2013;65:1731–1747.
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–1813.
   PubMed Web of Science ®Google Scholar
• McCready VR, Cornes P. The potential of intratumoural unsealed radioactive source therapy. Eur J Nucl Med. 2001;28:567–569.
   PubMedGoogle Scholar
• Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res. 2002;62:6712–6716.
   PubMed Web of Science ®Google Scholar
• Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001;7:1237–1245.
   PubMed Web of Science ®Google Scholar
• Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res. 2011;28:1819–1830.
   PubMed Web of Science ®Google Scholar
• Kohli AG, Kivimae S, Tiffany MR, et al. Improving the distribution of Doxil(R) in the tumor matrix by depletion of tumor hyaluronan. J Control Release. 2014;191:105–114.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813–827.
   PubMed Web of Science ®Google Scholar
• Zhu L, Torchilin VP. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb). 2013;5:96–107.
   PubMed Web of Science ®Google Scholar
• Bibi S, Lattmann E, Mohammed AR, et al. Trigger release liposome systems: local and remote controlled delivery? J Microencapsul. 2012;29:262–276.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids. 2012;165:424–437.
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, et al. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–4398.
   PubMed Web of Science ®Google Scholar
• Koning GA, Eggermont AM, Lindner LH, et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010;27:1750–1754.
   PubMed Web of Science ®Google Scholar
• Lai CY, Fite BZ, Ferrara KW. Ultrasonic enhancement of drug penetration in solid tumors. Front Oncol. 2013;3:204.
   PubMedGoogle Scholar
• Phillips WT, Bao A, Brenner AJ, et al. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev. 2014;76:39–59.
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951.
   PubMed Web of Science ®Google Scholar
• Durymanov MO, Rosenkranz AA, Sobolev AS. Current approaches for improving intratumoral accumulation and distribution of nanomedicines. Theranostics. 2015;5:1007–1020.
   PubMed Web of Science ®Google Scholar
• MacEwan SR, Callahan DJ, Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond). 2010;5:793–806.
   PubMed Web of Science ®Google Scholar
• Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release. 2015;219:192–204.
   PubMed Web of Science ®Google Scholar
• Lee H, Hoang B, Fonge H, et al. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res. 2010;27:2343–2355.
   PubMed Web of Science ®Google Scholar
• Saggar JK, Yu M, Tan Q, et al. The tumor microenvironment and strategies to improve drug distribution. Front Oncol. 2013;3:154.
   PubMedGoogle Scholar
• Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res. 2012;18:454–464.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383–388.
   PubMed Web of Science ®Google Scholar
• Temming K, Schiffelers RM, Molema G, et al. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat. 2005;8:381–402.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Koning GA, Ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003;91:115–122.
   PubMed Web of Science ®Google Scholar
• Asai T. Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels. Biol Pharm Bull. 2012;35:1855–1861.
   PubMed Web of Science ®Google Scholar
• Asai T, Oku N. Liposomalized oligopeptides in cancer therapy. Methods Enzymol. 2005;391:163–176.
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, Van Der Wal S, Le HT, et al. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci. 2012;45:429–435.
   PubMed Web of Science ®Google Scholar
• Dai W, Jin W, Zhang J, et al. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes. Pharm Res. 2012;29:2902–2911.
   PubMed Web of Science ®Google Scholar
• Fens MH, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer. 2008;99:1256–1264.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang T, Wang X, et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release. 2011;149:299–306.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Wang JC, Bian DY, et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm. 2010;74:467–473.
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007;67:9455–9462.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759–768.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031–1035.
   PubMed Web of Science ®Google Scholar
• Yan Z, Yang Y, Wei X, et al. Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue. Mol Pharm. 2014;11:218–225.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yan Z, Wei D, et al. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes. Nanotechnology. 2013;24:405101.
   PubMed Web of Science ®Google Scholar
• Eikenes L, Bruland OS, Brekken C, et al. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004;64:4768–4773.
   PubMed Web of Science ®Google Scholar
• Zheng X, Goins BA, Cameron IL, et al. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother Pharmacol. 2011;67:173–182.
   PubMed Web of Science ®Google Scholar
• Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A. 2011;108:2909–2914.
   PubMed Web of Science ®Google Scholar
• Eikenes L, Tari M, Tufto I, et al. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer. 2005;93:81–88.
   PubMed Web of Science ®Google Scholar
• Lu D, Wientjes MG, Lu Z, et al. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007;322:80–88.
   PubMed Web of Science ®Google Scholar
• Hylander BL, Sen A, Beachy SH, et al. Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model. J Control Release. 2015;217:160–169.
   PubMed Web of Science ®Google Scholar
• Geretti E, Leonard SC, Dumont N, et al. Cyclophosphamide-mediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302). Mol Cancer Ther. 2015;14:2060–2071.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Metselaar JM, Fens MH, et al. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia. 2005;7:118–127.
   PubMed Web of Science ®Google Scholar
• Li Z, Huang H, Tang S, et al. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials. 2016;74:144–154.
   PubMed Web of Science ®Google Scholar
• Madsen SJ, Baek SK, Makkouk AR, et al. Macrophages as cell-based delivery systems for nanoshells in photothermal therapy. Ann Biomed Eng. 2012;40:507–515.
   PubMed Web of Science ®Google Scholar
• Al-Ahmady ZS, Scudamore CL, Kostarelos K. Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: critical parameters and therapeutic efficacy. Int J Cancer. 2015;137:731–743.
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release. 2013;167:130–137.
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TL, Hossann M, et al. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release. 2013;168:142–150.
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TL, Haeri A, et al. A novel two-step mild hyperthermia for advanced liposomal chemotherapy. J Control Release. 2014;174:202–208.
   PubMed Web of Science ®Google Scholar
• Al-Ahmady ZS, Chaloin O, Kostarelos K. Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release. 2014;196:332–343.
   PubMed Web of Science ®Google Scholar
• Dicheva BM, Ten Hagen TL, Li L, et al. Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells. Nano Lett. 2013;13:2324–2331.
   PubMed Web of Science ®Google Scholar
• Dicheva BM, Ten Hagen TL, Seynhaeve AL, et al. Enhanced specificity and drug delivery in tumors by cRGD - anchoring thermosensitive liposomes. Pharm Res. 2015;32:3862–3876.
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee DW, Park K, et al. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes. Colloids Surf B Biointerfaces. 2014;116:17–25.
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274–279.
   PubMed Web of Science ®Google Scholar
• Fortin-Ripoche JP, Martina MS, Gazeau F, et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology. 2006;239:415–424.
   PubMed Web of Science ®Google Scholar
• Viroonchatapan E, Sato H, Ueno M, et al. Magnetic targeting of thermosensitive magnetoliposomes to mouse livers in an in situ on-line perfusion system. Life Sci. 1996;58:2251–2261.
   PubMed Web of Science ®Google Scholar
• Davies Cde L, Lundstrom LM, Frengen J, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res. 2004;64:547–553.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res. 2000;6:4939–4949.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Monsky WE, Girnun G, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res. 2003;63:6327–6333.
   PubMed Web of Science ®Google Scholar
• Moussa M, Goldberg SN, Kumar G, et al. Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy. PLoS One. 2014;9:e102727.
   PubMed Web of Science ®Google Scholar
• Soundararajan A, Dodd GD 3rd, Bao A, et al. Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model. Radiology. 2011;261:813–823.
   PubMed Web of Science ®Google Scholar
• Yang W, Ahmed M, Elian M, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257:685–696.
   PubMed Web of Science ®Google Scholar
• Yang W, Ahmed M, Tasawwar B, et al. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int J Hyperthermia. 2011;27:527–538.
   PubMed Web of Science ®Google Scholar
• Yang W, Ahmed M, Tasawwar B, et al. Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J Control Release. 2012;160:239–244.
   PubMed Web of Science ®Google Scholar
• Monsky WL, Kruskal JB, Lukyanov AN, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology. 2002;224:823–829.
   PubMed Web of Science ®Google Scholar
• Head HW, Dodd GD 3rd, Bao A, et al. Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology. 2010;255:405–414.
   PubMed Web of Science ®Google Scholar
• Moussa M, Goldberg SN, Tasawwar B, et al. Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature. J Vasc Interv Radiol. 2013;24:1021–1033.
   PubMed Web of Science ®Google Scholar
• Andriyanov AV, Koren E, Barenholz Y, et al. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes. PLoS One. 2014;9:e92555.
   PubMed Web of Science ®Google Scholar
• Grüll H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release. 2012;161:317–327.
   PubMed Web of Science ®Google Scholar
• Phenix CP, Togtema M, Pichardo S, et al. High intensity focused ultrasound technology, its scope and applications in therapy and drug delivery. J Pharm Pharm Sci. 2014;17:136–153.
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72:5566–5575.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Klibanov AL. Co-administration of microbubbles and drugs in ultrasound-assisted drug delivery: comparison with drug-carrying particles. Adv Exp Med Biol. 2016;880:205–220.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Maruyama K. Effective in vitro and in vivo gene delivery by the combination of liposomal bubbles (bubble liposomes) and ultrasound exposure. Methods Mol Biol. 2010;605:473–486.
   PubMedGoogle Scholar
• Yang F-Y, Wong -T-T, Teng M-C, et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. J Control Release. 2012;160:652–658.
   PubMed Web of Science ®Google Scholar
• Yin T, Wang P, Li J, et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014;35:5932–5943.
   PubMed Web of Science ®Google Scholar
• Yudina A, De Smet M, Lepetit-Coiffe M, et al. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J Control Release. 2011;155:442–448.
   PubMed Web of Science ®Google Scholar
• Dicheva BM, Seynhaeve AL, Soulie T, et al. Pharmacokinetics, tissue distribution and therapeutic effect of cationic thermosensitive liposomal doxorubicin upon mild hyperthermia. Pharm Res. 2016;33:627–638.
   PubMed Web of Science ®Google Scholar
• Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007;13:2722–2727.
   PubMed Web of Science ®Google Scholar
• Kheirolomoom A, Lai C-Y, Tam SM, et al. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J Control Release. 2013;172:266–273.
   PubMed Web of Science ®Google Scholar
• Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem. 2007;7:425–440.
   PubMed Web of Science ®Google Scholar
• Fowler RA, Fossheim SL, Mestas J-L, et al. Non-invasive magnetic resonance imaging follow-up of sono-sensitive liposome tumor delivery and controlled release after high-intensity focused ultrasound. Ultrasound Med Biol. 2013;39:2342–2350.
   PubMed Web of Science ®Google Scholar
• Kheirolomoom A, Kruse DE, Qin S, et al. Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release. 2010;141:128–136.
   PubMed Web of Science ®Google Scholar
• Watson KD, Lai C-Y, Qin S, et al. Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 2012;72:1485–1493.
   PubMed Web of Science ®Google Scholar
• De Smet M, Langereis S, Van Den Bosch S, et al. SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound. J Control Release. 2013;169:82–90.
   PubMed Web of Science ®Google Scholar
• De Smet M, Hijnen NM, Langereis S, et al. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin. Invest Radiol. 2013;48:395–405.
   PubMed Web of Science ®Google Scholar
• Negussie AH, Yarmolenko PS, Partanen A, et al. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia. 2011;27:140–155.
   PubMed Web of Science ®Google Scholar
• Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007;99:53–63.
   PubMed Web of Science ®Google Scholar
• Viglianti BL, Ponce AM, Michelich CR, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 2006;56:1011–1018.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res. 2000;6:2528–2537.
   PubMed Web of Science ®Google Scholar
• Ren S, Li C, Dai Y, et al. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection. J Pharm Pharmacol. 2014;66:1231–1239.
   PubMed Web of Science ®Google Scholar
• Bao A, Phillips WT, Goins B, et al. Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. Int J Pharm. 2006;316:162–169.
   PubMed Web of Science ®Google Scholar
• Saito R, Krauze MT, Noble CO, et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods. 2006;154:225–232.
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Ozawa T, Drummond DC, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013;15:189–197.
   PubMed Web of Science ®Google Scholar
• Phillips WT, Goins B, Bao A, et al. Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. Neuro Oncol. 2012;14:416–425.
   PubMed Web of Science ®Google Scholar
• Brandwijk RJ, Mulder WJ, Nicolay K, et al. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem. 2007;18:785–790.
   PubMed Web of Science ®Google Scholar
• Kuesters GM, Campbell RB. Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine (Lond). 2010;5:181–192.
   PubMed Web of Science ®Google Scholar
• Mulder WJ, Strijkers GJ, Habets JW, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J. 2005;19:2008–2010.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Aljehani ZK, Gazzaz RW, et al. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release. 2015;219:269–277.
   PubMed Web of Science ®Google Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37:63–74.
   PubMed Web of Science ®Google Scholar
• Stapleton S, Milosevic M, Tannock IF, et al. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. J Control Release. 2015;211:163–170.
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Warren G, Wei X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (Lond). 2014;9:695–707.
   PubMed Web of Science ®Google Scholar
• Goins BA, Phillips WT. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog Lipid Res. 2001;40:95–123.
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001;61:3027–3032.
   PubMed Web of Science ®Google Scholar
• Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res. 2000;6:3748–3755.
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Kostarelos K. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications. Nanomedicine (Lond). 2007;2:85–98.
   PubMed Web of Science ®Google Scholar
• Bakandritsos A, Fatourou AG, Fatouros DG. Magnetoliposomes and their potential in the intelligent drug-delivery field. Ther Deliv. 2012;3:1469–1482.
   PubMedGoogle Scholar
• Bulte JW, De Cuyper M. Magnetoliposomes as contrast agents. Methods Enzymol. 2003;373:175–198.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Y, Xiao D, et al. Low-dose chemotherapy of hepatocellular carcinoma through triggered-release from bilayer-decorated magnetoliposomes. Colloids Surf B Biointerfaces. 2014;116:452–458.
   PubMed Web of Science ®Google Scholar
• Kulshrestha P, Gogoi M, Bahadur D, et al. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. Colloids Surf B Biointerfaces. 2012;96:1–7.
   PubMed Web of Science ®Google Scholar
• Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2010;142:108–121.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Garg SK, Cohen P, et al. Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. Ann Surg Oncol. 2013;20 Suppl 3:S676–83.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249:364–374.
   PubMed Web of Science ®Google Scholar
• Kruskal JB, Oliver B, Huertas JC, et al. Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tissue in mice. J Vasc Interv Radiol. 2001;12:1193–1201.
   PubMed Web of Science ®Google Scholar
• Wood BJ, Poon RT, Locklin JK, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol. 2012;23:248–55 e7.
   PubMed Web of Science ®Google Scholar
• Manthe RL, Foy SP, Krishnamurthy N, et al. Tumor ablation and nanotechnology. Mol Pharm. 2010;7:1880–1898.
   PubMed Web of Science ®Google Scholar
• Fiandaca MS, Berger MS, Bankiewicz KS. The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel). 2011;3:369–397.
   PubMed Web of Science ®Google Scholar
• Mehta AI, Choi BD, Ajay D, et al. Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol. 2012;9:305–310.
   PubMedGoogle Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076–2080.
   PubMed Web of Science ®Google Scholar
• Li S, Goins B, Zhang L, et al. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem. 2012;23:1322–1332.
   PubMed Web of Science ®Google Scholar
• Allard E, Hindre F, Passirani C, et al. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging. 2008;35:1838–1846.
   PubMed Web of Science ®Google Scholar
• Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg. 2008;108:989–998.
   PubMed Web of Science ®Google Scholar
• Mehta AI, Choi BD, Raghavan R, et al. Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel). 2011;3:201–206.
   PubMed Web of Science ®Google Scholar
• Rainov NG, Heidecke V. Clinical development of experimental virus-mediated gene therapy for malignant glioma. Anticancer Agents Med Chem. 2011;11:739–747.
   PubMed Web of Science ®Google Scholar
• Shultz MD, Wilson JD, Fuller CE, et al. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology. 2011;261:136–143.
   PubMed Web of Science ®Google Scholar
• Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66:2801–2806.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010;113:301–309.
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol. 2015;17 Suppl 2:ii3–ii8.
   PubMed Web of Science ®Google Scholar
• Barua NU, Gill SS, Love S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol. 2014;24:117–127.
   PubMed Web of Science ®Google Scholar
• Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64:2572–2579.
   PubMed Web of Science ®Google Scholar
• Allard E, Passirani C, Benoit J-P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30:2302–2318.
   PubMed Web of Science ®Google Scholar
• French JT, Goins B, Saenz M, et al. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol. 2010;21:1271–1279.
   PubMed Web of Science ®Google Scholar
• Chen R, Braun GB, Luo X, et al. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. 2013;73:1352–1361.
   PubMed Web of Science ®Google Scholar
• LeBleu VS. Imaging the Tumor Microenvironment. Cancer J. 2015;21:174–178.
   PubMed Web of Science ®Google Scholar